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Previous studies have demonstrated that the positron .
emitting fluorine-18 ("F)-Rbelod flnoromlsooidazok is a
specific tracer of myocardial hypoxia . Its fraetlenal extrac-
dan to enhanced In isehemic or hypoxic myocardium but
returns to baseline levels en reperfusion and recovery of
normal function. Thus, ibis agent might be useful in
delineating acutely hypoaic but potentially salvageable
myocardium. Accordingly, to delineate the relation be
.
twren the un oeardid extraction of °F•guoromhenlazole
alter intravenous administration and the time of antecedent
lachemla in vivo, uptake of tracer was measured with
positron emission tomography and direct postmortem Its.
sue analysis In 14 dogs In which tracer was administered
within 3 h of coronary oceluslon (a time associated with
marked potential for salvage on reperfusion)
; in 4 dogs
after 6 h of coronary occlusion (a time associated with
minimal salvage of myocardium on reperfuslon); and In 8
dogs alter >24 h of coronary occlusion (to delineate uptake
in tissue that Is Irreversibly damaged) .
The measurement of myocardial blood flow and flow reserve
after exercise or pharmacologic stress constitutes the pri-
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The
residual
section (that is, the amount of tracer
extracted and retained In a region) In ixhemic myocardum
in the dogs in which rF- was admL[s-
tered within 3 h alter occlusion averaged (t standard
deviation) 23 * 18%, which was higher than the red"
fraction in myocardium subjected to keheala for either 6
or >24 h before tracer administratlen (12 t 7% and 5 t
2%, respectively, p < 0.817or both). Retention of tracer In
remote normal myocardium averaged 2 t 1% .
Because marked nhutemal of extraction of taF-
fluoromisonidamk occurred in myoardium only early
after the Isehernle bond, this agent may hold promise
for the noninvaalve Identification of jeopardized but
salvageable myoardhtm, In addition, h should be useful
in enhancing the uadeevtandl-g of the basic role of myo-
cardial hypoxia In cardiac disease and its response to
treatment .
fJ Am Cell CardieJ 1998,16:477-85)
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mary approach for the diagnosis of coronary artery disease
and its response to therapy . Nonetheless, the determination
of the origin and pathophysiologie importance of chest pain,
especially in the acute setting, is more difficult. The positron-
emitting radiotracers fluorine-18 ("'IF) fluorodeoxygtucose
and rubidium-82 have been proposed for use in identifying
jeopardized myocardium (1-5). However, the dependence of
myocardial uptake and retention of either 18F-fluoredeoxy-
glucose or rubidium-82 on several factors, such as the
metabolic status of the myocyte and circulating levels of
substrate and hormones, myocardial flow and duration of
ischemia before tracer administration, have complicated the
use of these radiopharmaceutical agents (5-10). Because the
measurement of tissue oxygenation may be a more direct
07351097Nw93.50
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Figare 1. Schematic diagram of the proposed metabolism of fluo-
rine.18 fluoromisonidazole (18F-FMISO) in the heart . R-NO, =
reduced nitrate.
indicator of the balance between flow and oxygen demand
(or consumption), it may also be a sensitive and specific
marker of myocardial ischemia .
Accordingly, we (I1) as well as others (12) have been
evaluating the utility of the positron-emitting radiotracer
1tF-fluoromisonidazole (half-time 110 min) for the detection
of myocardial hypoxia . In isolated perfused hearts, we
previously demonstrated that fractional extraction of this
tracer is enhanced in ischemic or hypoxic myocardium .
Reperfused tissue demonstrated normal binding kinetics
concomitant with recovery of function, suggesting that 18F-
liuoromisonidazole holds promise for the noninvasive iden-
tification of jeopardized but potentially salvageable myocar-
dium .
In tumor cell models (13-15), labeled fluoromisonidazole
is taken up in proportion to the level of tissue hypoxia in
viable cells, but is not retained by necrotic cells . The
proposed mechanism of accumulation and retention of fluo-
romisc,nidazole in hypoxic tissue first involves diffusion of
the lipophilic tracer across the cell membrane, where the
nitro group undergoes reduction by ubiquitous cellular re-
ductase enzymes to form the reactive enzyme radical
(Fig . 1) . In the presence of oxygen, the favored subsequent
reaction is donation of the electron to the oxygen molecule
to form the superoxide anion, with regeneration of the
lipophilic parent compound, which is then free to diffuse
back across the cell membrane . In hypoxic tissue, the
reactive nitro anion may covatently bind to intracellular
macromolecules or undergo further nitroreduction, thereby
becoming irreversibly trapped (16-18) . We hypothesized
that necrotic myocardium should exhibit less binding be-
cause its capacity for enzymatic nitroreduction is dimin-
ished. In addition, intracellular trapping of macromolecules
may be decreased because of loss of sarcolemmal integrity .
Although our results in isolated perfused hearts were
promising, translation into an intact in vivo preparation is
associated with several potential problems, including the
high residual blood activity of tracer that potentially ob .
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scores enhanced extraction into myocardium, limited deliv-
ery of tracer to regions supplied by occluded vessels and the
occurrence of matched decreases in myocardial oxygen
consumption and oxygen demand in myocardium with di-
minished flow, resulting in negligible net tissue hypoxia .
Accordingly, the objective of the present study was to
determine whether uptake of 1tF-fluoromisonidazole is en-
hanced in ischemic but potentially viable myocardium in
intact dogs and, if so, whether the enhanced uptake could be
quantified by positron emission tomography .
Methods
Experimental preparation . The experimental studies per-
formed conform to the "Position of the American Heart
Association on Research Animal Use ." Dogs were fully
anesthetized during all of the experimental procedures .
After an overnight fast, 46 dogs weighing between 20 and
25 kg were premedicated with subcutaneous morphine
(I mg/kg body weight) and anesthetized with intravenous
thiopental (12,5 mg/kg) and alpha-chloralose (72 mglkg) . The
left femoral artery and vein were cannulated for measure-
ment of arteriai pressure and administration of drugs . Under
fluoroscopic guidance, a left atria) catheter was positioned
through the right femoral artery for administration of radio-
labeled microspheres . Dogs were then subjected to acute
occlusion of the left anterior descending coronary artery
with placement of a thrombogenic copper coil into the artery
in a closed chest preparation, as described previously (19) .
Complete coronary occlusion was documented angiograph.
ically .
Experimental protocol. To ascertain whether 1'F .
fluoromisonidazole uptake is enhanced in ischemic but po-
tentially viable myocardium compared with uptake in normal
nonischemic myocardium and relative to uptake in irrevers-
ibly damaged myocardium, three groups of dogs were stud-
ied. Fourteen dogs received '8F-fluoromisonidazole within
3 h of coronary occlusion . Previous work from our labora-
tory (19-21) demonstrated that reperfusion of the myocar-
dium within this time interval is associated with significant
metabolic salvage. Four dogs received tracer 6 h after
coronary occlusion to delineate 1aF-fluoromisonidazole ki-
netics in tissue that contains only minimal amounts of
salvageable myocardium after reperfusion (19,22) . Eight
dogs received tracer >24 h after occlusion . This time was
chosen to delineate "'F-fluoromisonidazole uptake in myo-
cardium not amenable to metabolic salvage (19). Dogs stud-
ied >24 h after occlusion ..ere allowed to recover after initial
coronary embolization, and then reanesthetized the foll„w-
ing day .
Of the 46 dogs entered into the protocol, 9 died from
ventricular fibrillation after coronary occlusion . Thirty-
seven dogs were subsequently studied after administration
of 1°F-fluoromisonidazole . Thirteen dogs were retrospec-
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tively found to have levels of myocardial perfusion in the
region supplied by the occluded artery >40% of how in
remote normal regions as a result of flow from collateral
arteries or very distal coronary occlusion . Therefore, the
anterior region was riot truly jeopardized (23) and data from
these dogs were analyzed separately . Thus, 24 dogs had true
ischemia. Two of these dogs had an initial study within 3 h of
occlusion and received repeat administration of '"F-
tluoromisonidazole 24 h after the initial study .
To delineate the region supplied by the occluded artery .
just before the dogs were euthanized with intravenous thio-
pental and saturated potassium chloride . 50 ml of a I%
solution of Lissamine green was administered intravenously .
Multiple myocardial samples were taken from remote nor-
mal regions as well as from within the region devoid of vital
dye, and counted in a gamma well scintillation counter .
Samples were recounted 72 h later to assay radioactivity
attributable to microspheres after decay of radioactivity
from "F-fluoromisonidazole
.
Determining the extent of infarction . The uptake of '"F-
fluoromisonidazole in infarcted tissue was also correlated
with macroscopic histochemical evidence of infarction with
the use of triphenyltetrazolium chloride . Two hundred mil-
liliters of a 1% solution (weight/volurte) of 2,3,5-triphenyl-
tetrazolium chloride (Sigma Chemical) in sodium phosphate
buffer (pH 7 .4) was administered intravenously just before
sacrifice . The heart was then cut into I cm transverse slices
and incubated in a 1% solution of triphenyltetrazolium
chloride at 37°C for optimal color development. Areas of
infarction were defined as those that retained "normal
myocardial color." We did not use the triphenyltetrazolium
chloride technique in dogs with ischemia of <24 h duration
because the biochemical processes (loss of coenzymes and
dehydrogenases responsible for the tetrazolium reaction to
diformazan) are not complete until 24 h after occlusion (24)
and, in dogs, the transmmal extent of infarction is not
complete until w24 h after occlusion (25) . Accordingly, false
positive tetrazolium staining can occur in hearts studied
early after occlusion.
Positron emission tomography. Animals studied with
positron emission tomography were secured in a Plexiglas
shell and positioned in the PETT Vl tomograph, which
permits simultaneous acquisition of seven transverse slices
and has a reconstructed resolution of 12 mm (full width at
half-maximum) . After a 20 to 30 min attenuation scan 1300 to
600,000 countsislice per scan), myocardial perfusion was
delineated by administering 25 to 30 mCi of oxygen-l5-
labeled water (H
215
0) intravenously . Data were collected for
90 s. To delineate the blood pool, after 5 to 10 min to allow
decay of radioactivity from K
.'
50 (half-time 2 .1 min). 40 to
50 mCi of oxygen-l5-labeled carbon monoxide (C 150) was
administered by ventilating the animals for one or two
breaths with air containing tracer . After allowing I min for
radioactivity to clear the lungs, data were collected for 5
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min
. For delineation of the distribution of myocardial blood
flow, data obtained with H,
130 were corrected for intravas-
cular tracer, as described previously (26) . Ten minutes after
the C 150 scan, a bolus injection of 5 to 13 mCi of tsF-
fluoromisonidazole was given intravenously and eight 5 min
sequential static images were obtained over 45 min . Because
arterial clearance of "F-fluoromisonidazole was also pro-
longed. tomographic reconstruction of the data were cot-
reeted for blood pool radioactivity in an analogous
fashion.
Because the resolution of the current generation of tomo .
graphic instruments is poor in comparison with the thickness
of the myocardium imaged and because we wanted to relate
the uptake of "F-Huoromisonidazole with myocardial blood
flow precisely, gamma-emitting radiolabeled microspheres
(15 pin) were administered concurrently with the adminis-
tration of H 2 1S0 in each dog . Myocardial blood tow esti-
mated by the standard reference technique (27) was calcu-
lated in each postmortem tissue sample and correlated with
tracer activity
.
Analysis of romogaphic data. For data analysis. three
individual regions of interest (volume approximately 0 .9 cm3
each) were assigned to the normal myocardial wall in a
midventricular tomographic reconstruction . Three regions of
interest were likewise assigned to the anterior ischemic
region, and a region of interest was assigned to the center of
the left atrial blood pool cavity to assess activity of tracer in
arterial blood . Counts in each region of the
1
"F-fluoromis-
onidazote images were corrected for decay, but not for
partial volume and spillover effects
. The same regions were
assigned to the myocardial blood flow image obtained with
H . 1 S0, and oxygen-15 counts in these regions were obtained
for calculation of relative regional blood flow as has been
previously described (26).
"'IF-fluoromisonldawle residual fraction map
. The
amount oft"F-fluoromisonidazo)e remaining within the myo-
cardium with time is proportional to the fractional extraction
of tracer (that is. proportional to the degree of tissue
hypoxia), the delivery of tracer to a given region (flow) and
myocardial retention of tracer
. This residual fraction can be
represented tomographically by the voxel by voxel division
of the '"F-fluoromisonidazole image by the H 2130 image
. To
generate this residual fraction map, the image obtained 45
min after "F-fluoromisonidazole administration and the
H,"0 perfusion image were first smoothed with a nine point
filter after correction of both images for tracer still in the
vasculature. The endocardial border was defined using the
area outside the 50% isocount contour of the C
1S0 blood
pool image (28). and the epicardial border myocardium was
defined from the perfusion or attenuation image
. Areas
outside the myocardium were set to zero . In addition, all
voxels in the H,1°0 image with <5% of maximal counts were
set to 5% to avoid division by zero
.
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Direct determination of "F-fluoromiwudazole residual
fraction
. The myocardial residual fraction of this tracer in a
region of interest can be calculated by the expression :
C,(t) = Q x ResFx x
f
Cs(t) dt - WO.
where the myocardial activity (C T [t]) is equal to the flow (Q)
times the residual fraction (ResFx) times the arterial input
function (Calt]) minus the amount of initially extracted
tracer that washes out of the myocardium (WO) .
In isolated
hems, we have shown (I1) that back-diffusion of tracer was
negligible (biologic half-time >40 ± 6 h) . Accordingly, for
the purpose of this study, WO was set to a value of zero .
This equation was used to calculate the residual fraction in
each postmortem sample of myocardium to precisely evalu-
ate the kinetics without the problems of partial volume and
spillover that can influence tissue radioactivity content as-
sessed with positron emission tomography and to correlate
tracer uptake with flow at greater resolutions than achiev-
able with this technique . The input function was obtained
from direct sampling of arterial blood.
Subcellular distribution or ' 817-fluoromisonidazole . To
determine
the subcellular distribution of extracted trF-
fluoromisonidazole, myocardium was fractionated into nu-
clear, mitochondrial, microsomal and cytosolic components
using a modification of standard separation techniques (29-
31) in four dogs. Briefly, myocardial samples (approximately
I g each) were rapidly excised from anterior ischemic
regions and normal posterolateral myocardium and placed in
ice-cold homogenizing buffer (containing 0 .25 M
sucrose and
0.01 M Tris buffer, pH = 7 .8), and total tracer radioactivity
was assessed by well counting . Tissue was then minced with
scissors and diluted with buffer to make a 10% weight/
volume mixture . The mixture was homogenized on ice with
a polytron, and centrifuged at 1,200 g for 15 min . The pellet,
which contained unruptured muscle tissue and nuclei, was
counted for tracer radioactivity. The supernatant was placed
in 50 ml tubes and centrifuged at 26,000 g for 15 min
. The
resultant pellet contained mitochondria and was subse-
quently counted for "'17-fluoromisonidazole activity . The
supernatant was placed in 25 ml plastic high speed tubes and
centrifuged at 105,000 g for 60 min in the NA Beckman
Ultracentrifuge . The pellet contained myocardial mi-
crosomes and the supernatant contained the cytosolic frac-
tion, and these were separated for determination of
' r
F-
fluoromisonidazole activity . The tracer activity in each of
the four fractions (nuclear, mitochondrial, microsomal and
cytosolic) was expressed as a percent of counts in the initial
sample of myocardium before subfractionation .
Synthesis of no carrier added 3-I'
t
Fl-fiuorod(2-nitral-
imidazolyl)-2-propanol (fluoromisonidazole) . No carrier
added "F-fluoromisonidazole was synthesized, as recently
reported (32) . Radiochemical purity, determined by high
JACC Vol . 16, No. 2
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performance liquid chromatography, was consistently
>99%
. and estimated specific activity was >400 Cilmmol
.
Tracer was dissolved in normal saline solution and was
radiochemically stable for at least 6 h at room temperature .
Statistical analysis. Data are expressed as mean values t
SD
. Comparison of unpaired samples was
subjected
to
analysis of variance, followed by t tests corrected for the
number of comparisons using the Bonferroni correction .
Linear regression was calculated by the least squares
method . Probability <0.05 was taken to indicate a statisti-
cally significant difference.
Results
1°F-rluoromtsonidazole kinetics In myocardium . Figure 2
shows four sequential tomograms from a dog given trF-
fluoromisonidazole 75 min after coronary occlusion . These
images (5 min each) were centered approximately 2.5, 15, 30
and 45 min after tracer administration . Typically, 300,000 to
1 .5 million countsislice per 5 min were obtained . All images
were corrected for tracer still in the blood pool. Activity in
the normal myocardium cleared with time, while activity
accumulated in the ischemic region with time . Also demon-
strated in these tomograms are the irregularities in the
anterior chest wall, which are due to tracer uptake in the
large anterior chest wall muscle in the dog .
By
45 min after
16F-fluoromisonidazole injection, skeletal muscle uptake
closely approximated normal myocardial muscle uptake and
paralleled blood tracer activity . The locus of the anterior
radioactivity as emanating from skeletal muscle was docu-
mented in postmortem samples from several dogs.
Blood and myocardial time-activity carves
obtained
from
this same dog are shos
•a in Figure 3 . After the initial
distribution phase, blood pool activity decreased slowly with
time and remained elevated at 45 min. Activity in normal
myocardium approximated the decrease in blood pool activ-
ity. In contrast, tracer continued to accumulate in the
ischemic anterior myocardium although flow was only 10%
of normal in this dog. By 20 to 25 min after tracer adminis-
tration, counts in the ischemic region exceeded those in
normal myocardium.
Residual fraction or
"F-Buorondsotddazale, A myocardial
residual fraction map is shown in Figure 4, where the
16 F-fluoromisonidazole tomogram, the H,
11
0 image and the
"F-fluoromisonidazole residual fraction map graphically
highlight the enhanced extraction of "'F-111uoromisonidazole
in the large anterior ischemic area in a dog that received an
injection 3 h after occlusion . The example shown in Figure 5
depicts diminished 16F-fluoromisonidazole in the center of
the anterior ischemic region of a dog that received tracer 6 h
after acute coronary occlusion
. However, 1
BF-fluoromisoni-
dazole residual fraction is enhanced at the lateral borders of
the ischemic region . There was close agreement between the
ratio of the counts in abnormal regions with counts in the
F%= 2 . Sequential midventricutar tomographic tconstructions ob
pained from 5 min scans at 2 .5 (upper left), 15 (upper right). 30 (bottom
left) and 45 min (bottom right) after administration of "F-
fluaromisanidazok in a dog with 75 min of coronary artery occlusion .
All images are corrected for tracer remaining in the blood pool.
Initially, 'IF-fluoromisonidazole distributes in proportion to blood
flow, but then clears from normal myocardium as the blood tracer
concentration decreases. In contrast, tracer progressively accumulates
in ischemic myocardium . 1n this and all subsequent tomogams, the
anterior myocardium is to the top, septum to the right. lateral myocar-
dium to the reader's left and posterior myocardium at the human .
Figure 4 . Tomographic reconstructions of 'IF-fluoeomisonida+ .ole
(upper left) 45 min after administration of tracer, myocardial blood
How obtained after administration of oxygen-IS-labeled water
(112150) (lower left) and the myocardial ' I F-fluoromisonidazole re-
sidual fraction map (upper right) obtained in a dog with 3 h of
occlusion, showing marked enhancement of tracer throughout the
ischemic, anterior region . The extraction map was obtained by a
voxel by voxel division of tracer activity by the flow image (see
text) .
Figure 3. Time-activity data obtained noninvasively from left atrial
blood pool . normal lateral myocardial
and ischemic anterior myo-
cardial regions of interest from the dog whose tomograms are shown
in Figure 2. Radioactivity in normal myocardium diminishes with
the blood pool, whereas radioactivity in the ischemic myocardium
increases with time and by 15 min is greater than that in the normal
myocardium. cps = counts ; PET = positron emission tomogaphy.
Figure 5 . Midventricular tomogmphic reconstructions of ' I
F-
fluoromisonidazole (upper left) obtained 45 min after administration
of tracer. blood flow (lower loft) and "F-Huommisonidazole residual
fraction (upper right) in a dog in which 'IF-fluoromisonidazok was
administered 6 h after coronary occlusion . The residual fraction in
the center of the ischemie region is low, consistent with irreversible
damage . However, tracer activity is enhanced at
the lateral margins
of the ischemic region, consistent with potentially viable myocar-
dium .
MICROSPHERE FLOW Ira/4m/min)
normal regions obtained from the positron emission tomo-
graphic (PET) map and values assayed directly by well
counting
(YPET = 0•94XDIRECT -
0.7, r = 0.93, n = 6 dogs),
The myocardial residual fraction of 18Ffluoromisonida-
zole was calculated in each postmortem sample of myocar-
dium to precisely evaluate tissue radioactivity without the
problems of partial volume and spillover and to correlate
uptake with flow at greater resolutions than can be achieved
with positron emission tomography . The residual fraction of
18F-fluoromisonidazole in ischemic myocardium from the 14
dogs in which tracer was administered within 3 h after
occlusion averaged 23 ± 18% compared with 2 ± 1% in
remote normal myocardium in these animals
(p < 0.001).
The residual fraction was 12 s 7% in the ischemic regions in
the four dogs subjected to 6 h of occlusion before tracer
administration (p < 0 .01 compared with the 3 h group) and
5 ± 2% in the ischemic myocardium from the eight dogs that
had ischemia for 24 h before tracer administration (p < 0 .001
compared with the 3 h group). The residual fraction in
myocardium in dogs with coronary occlusion but in which
flow was not decreased to <40% of normal as a result of
collateral flow was 3 ± 2% (n = 13), which was not
statistically different from that in normal myocardium from
these dogs (2 ± 2%).
The results obtained from the 14 dogs that received Lo-
1°F
fluoromisonidazole within 3 h of occlusion are shown in
Figure 6,
which depicts the relation between calculated
residual fraction per tissue sample and microsphere
flow in
208 myocardial samples. The residual fraction did not ex-
ceed normal values until the flow was <0.4 mUg per min,
most likely indicating that tissue hypoxia does not occur
until the flow is diminished below this level. Within this
group (which received tracer within 3 h of occlusion), there
was no correlation between the residual fraction and the time
of antecedent ischemia. Residual fraction in normal myocar-
dium averaged 2 ± I%, which was in very close agreement
with the value we obtained in isolated perfused hearts (1I).
The group results of calculated residual fractions using
data obtained
from postmortem samples in all three groups
of dogs is depicted in Figure 7
. At any given value of
ischemia, the 18
F-fluoromisonidazole residual fraction was
Figure 6. Calculation of "F-fluoromisonidazole
(' FM) residual fraction compared with blood flow in
209 samples of myocardium obtained from 14 dogs in
which tracer was administered within 3 h of occlusion.
Residual fraction does not increase until flow is <0 .4
mUg per min . Within this group of dogs, there was no
correlation between the duration of antecedent isch-
emia and the residual fraction value .
much less when tracer was administered >24 It after occlu-
sion compared with administration of tracer either within 3 h
or >6 h after occlusion.
The difference between 1°F-
fluoromisonidazole residual fraction in ischemic myocar-
dium from dogs that received tracer within 3 h compared
with that in dogs that received tracer >24 hours after
occlusion was statistically significant (p < 0 .01) at all flow
ranges.
Triphenyttetrazolium chloride was administered intrave-
nously in all dogs in which ischemia was present for >24 h to
macroscopically delineate zones of infarction . In these dogs,
the increased 1BF-fluoromisonidazole extraction fraction was
only observed in areas of infarction (data not shown) .
Figure 7. Summary of data from all 24 dogs in the three groups
comparing the residual friction of 11 F-fluoromi .rm
icia
+ele with
myo-
cordial blood flow. At all flow ranges, ischemic myocardium in dogs
in which grocer was administered at 6 or >24 h afterocclusion . In all
regions with myocardial blood flow >0 .4 mtg per min, the residual
fraction was not different from that of remote normal
myocardium.
Numbers at the bottom of each bar indicate the number
of samples
evaluated.
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Table L Percent of Total 11 F-Fluoromisonidazole Radioactivity in
Subcelluarr Fractions
Cytosdic Nuclear Mitahondrial Microsomal
	
%
Friction Fraction Fraction Fraction Recovery
Normal 56±3 25±6 2.6±1 .0 1 .3±0 .3 84±7
myocardium
Ischreic 55t2 26t2 2.5 ± 0 .8 1 .2 x 0 .5
87 x 3
myoeordam
The subueltulu disuibutioo of radioactivity was evatualvd in muhipte
myocudel samples assayed in duplicate from
four dogs with tracer adreinis-
temd within 3 h of occlusion. The majanty ofactivity resides in the cytosdk
fraction, with lessor amounts in The nuclear, mitahondrial and microsomal
fnctfons.
Sobee lular distribution of tracer activity in myocardium.
The subcellular distribution of '5 l -fluoromisonidazole activ-
ity in myocardium was assessed from duplicate samples of
normal and ischemic tissue in four dogs in which it was
administered within 3 h of coronary occlusion . The percent
recovery of the original counts in each sample was X80% in
all cases. There was no statistical difference between the
amount of tracer in any of the four subcellular fractions
when ischemic tissue was compared with normal tissue .
Radioactivity in the cytosolic fraction accounted for the
majority of tracer(55% to 65%). Radioactivity in the nuclear,
mitochondria) and microsomal fractions represented approx-
imately 25%, 2% and <2% of total myocardial radioactivity,
respectively (Table I)
.
Discussion
Nonlavaaive disgaesis of hlfrcted and viable myocardium
.
The noninvasive diagnosis of coronary artery disease and its
response to therapeutic interventions currently relies on the
measurement of myocardial blood flow at rest and of flow
reserve after exercise or phalmacologic coronary vasodila-
tion (33) . Myocardial infarction can be diagnosed with
positron emission tomography by sustained concomitant
decreases in myocardial blood flow and either oxygen con-
sumption (measured with carbon-I h acetate) (34) or glyco-
lytic flux (measured with "'F-fluorodeoxyglucos s) (35). Even
though noninvasive assessment of myocardial oxygen con-
sumption with carbon-11 acetate is a valid and valuable
technique (34,36,37), we have demonstrated that after reper-
fusion, recovery
of oxygen consumption, although predic-
tive of recovery of regional wall motion, is delayed in both
experimental and clinical studies (38,39) . Accordingly, even
after successful reperfusion, early assessment of total re-
gional myocardial oxygen consumption may not predict
viable myocardium. Both '°F-fluorodeoxyglucose and rubid-
ium-82 have been proposed for the assessment of viable
myocardium (1-5). However, the uptake of these agents is
dependent on the metabolic state of
the myocyte, on flow
itself and on the pattern of substrate use
(6-8). In addition,
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the number of patients in whom a "mismatch" between flow
and 18F-fluorodeoxyghcose has been shown to predict even-
tual functional recovery of myocardium is small (1) . In
patients with infarction, functional recovery in regions with
a flow/fluorodeoxyglucose mismatch is variable
(2).
Myocardial uptake of lturamYaaldoale. The measure-
ment
of tissue oxygenation may be the best indicator of the
balance of flow and oxygen consumption, and may be the
most sensitive and specific predictor of the physiologic
significance of coronary artery disease and its response to
therapy
. The hypoxic sensitizer, "IF-fluoromisonidazole of-
fers a noninvasive approach for the direct assessment of
tissue hypoxia in jeopardized but potentially salvageable
myocardium, We previously demonstrated (11) in isolated
perfused hearts that this compound is a specific tracer of
myocardial tissue hypoxia . Work by several other groups
(13-I5) has shown that in tumor cell models, this tracer is
taken up in proportion to the level of tissue hypoxia in viable
cells
. but is not retained by necrotic cells . In a myocardial
cell preparation, Cerqueira et al . (40) have confirmed that
"'IF-fluoromisonidazole is taken up in poportion to the level
of tissue hypoxia in viable cells .
To date, there have been no data on the uptake of
' °
Ffuoromisonidazole in relation to flow and with respect to
the
duration of antecedent ischemla. The results of our
current study indicate that extraction of this tracer is en-
hanced in ischemic myocardium in vivo when the
adminis-
tration
of tracer was made within 3 h of coronary artery
occlusion, at a time known to be associated with marked
potential for salvage on reperfusion (19-21) . The extrrvrdoa
was decreased but still significantly greater than onmaai in
ischemic areas when "IF-fluoromisonidazole was injected 6 h
after coronary occlusion
. By 24 h
. thane was a marked
decrease in 'aF-fluoromisonidazo(e residual fraction, cn rre-
sponding to a time previously demonstrated to be associated
with irreversible changes. Because we wanted to perform
well counting after sustained occlusion in this initial study,
these results do not demonstrate the ability of enhanced
uptake
of
this tracer during ischemia to identify myocardium
that would recover functionally after r . yerfusion, but studies
(II) in isolated perfused hearts have shown that ischemic
tissue recovered normal "IF-fluoranisonidazole kinetics
concomitant with full recovery of function after reperfusion .
Accordingly, we believe that "IF-fluoromisonidazole may
hold promise as a tracer for the noninvasive identification of
jeopardized but salvageable myocardium .
In dogs with tracer within 3 h of occlusion, increased
residual fraction was observed only in samples of myocar-
dium with flows <0.4 mlg per min (corresponding toapprox-
imately 40% of normal flow in these animals). These findings
are consistent with the concept that true tissue hypoxia does
not occur until flow has been decreased below this level-
Calculated residual fractions have probably been overesti-
mated in the group with extremely low flow values (between
484 SHELTON ET AL
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0 and 0 .05 mug per min) because of division by small
numbers . Although we feel confident that the values pre-
sented for residual fraction are valid, we cannot exclude
admixtures of viable and irreversibly injured tissue in the
samples because ischemic regions in dogs are relatively
heterogeneous histologically (22,23) .
Although our postmortem counting demonstrates that
"F-fuoromisonidazole extraction is enhanced in ischemic
myocardium early after the acute insult, uptake is time
dependent and probably related to the integrity of the
myocyte, including sarcolemmal membrane phospholipid
composition and fluidity and levels of the intracellular en-
zymes necessary for nitroreduction of "F-fluoromisonida-
zole. Thus, myocardium early after ischemia retains a sig-
nificant fraction of the '°F-fluoromisonidazole that diffuses
into the cell, while myocardium later after ischemia does not
retain as much . With the onset of irreversible injury, reten-
tion is minimal but not
zero,
probably because of islands of
residual viable myocardium within the infarct in this exper-
imental preparation
.
Imaging of "F-fluoromisonidazole uptake . Although in
some instances (as in the tomograms shown in Fig . 2, 4 and
5), ischemic myocardium can be visualized by "positive"
uptake in the ischemic myocardium within 45 min after
administration of tracer, this was not the case in all dogs .
Because coronary occlusion induces profound ischemia and
limits tracer delivery despite enhanced fractional extraction,
in some dogs, the only way to demonstrate enhanced uptake
of ' aF-fluoromisonidazole was to construct the extraction
map by dividing the "F-fluoromisoaidazole image by the
flow image
. Martin et al . (12) have demonstrated that with
prolonged imaging times (that is
. 4 h) positive images of
ischemic tissue are possible because the blood 'tF-
fluoromisonidazole concentration decreases slowly and nor-
mal myocardium is in relative equilibrium with the blood
pool. As demonstrated by the tomographic images in Figure
2, it may be possible to use "F-fluoromisonidazole scans
early after intravenous administration to delineate the distri-
bution of perfusion so that a separate blood flow imaging
agent is unnecessary
. We decided to limit the imaging
sequence to 45 min after administration of °F-fluoromisoni-
dazole to assess whether this tracer might be applicable
clinically to situations in which rapid assessment of viability
is needed .
5ubeellulur distribution, There was no significant differ-
ence in the subcellular distribution of tracer activity between
normal myocardium and ischemic myocardium, consistent
with the proposed mechanism of binding of 'gF-fluoromis-
onidazole (13-18). Because some trapping of the reactive
nitro anion early after diffusion of the compound into the cell
might be expected to occur before the scavenging of the
electron by oxygen, a small degree of binding of tracer in
normal myocardium is to be expected
. The only difference in
binding in hypoxic compared with normal myocardium may
be due to differences in relative amounts of 'gF-
fluoromisonidazole trapped, rather than due to different
binding mechanisms. The relative distribution of this tracer
in the subcellular fractions is consistent with the proposed
nonspecific binding of the nitro group with intracellular
macromolecules (t3-18) .
Ctiminl imputations. The results of the present study
indicate that
f
°F-fluoromisonidazole accumulates in ische-
mic myocardium when administered early after coronary
occlusion. Previous experimental studies (1l) have demon-
strated that the mechanism for uptake is related to actual
tissue hypoxia rather than to flow itself. When tracer was
administered after long duations of ischemia, the residual
fraction was diminished, probably indicative of the transition
from reversibly to irreversibly injured myocardium, and
probably dictated by the leakage of intracellular enzymes
that are necessary for "F-fluoromisonidazole binding within
the myocyte
. If future studies demonstrate that the ability of
the myocardium to accumulate '°F-fluoromisonidazole is
associated with its ability to recover functionally after reper-
fusion, then this agent or other tracers in its class with more
favorable blood pool clearance hold particular promise for
the rapid identification of patients with myocardial hypoxia
within the time constraints in which interventions may be
beneficial and may permit the rapid noninvasive identifica-
tion of patients with myocardial hypoxia, such as occurs
during episodes of unstable angina. In addition, this agent
should be useful in enhancing our understanding of the basic
role of tissue hypoxia in a variety of cardiac disorders and its
response to therapeutic interventions .
We thank Coda Weimwimer, James Bakke and Howard target for tmheksl
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